The reason Leronlimab did not demonstrate a substantial improvement over existing therapies was at least in part the mOS, which was approximately six months. However, 88 percent of the patients given a higher dose (525 or 700 mg) demonstrated a significant response to Leronlimab, and as we now know, 100 % of the patients who demonstrated that response and were given Leronlimab plus an ICI survive, now, five years later. That would I believe be additional data that would merit revisiting and in fact reapplying for a BTD.